Daewon Pharm
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemuls… Read more
Daewon Pharm (003220) - Net Assets
Latest net assets as of September 2025: ₩263.87 Billion KRW
Based on the latest financial reports, Daewon Pharm (003220) has net assets worth ₩263.87 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩606.37 Billion) and total liabilities (₩342.50 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩263.87 Billion |
| % of Total Assets | 43.52% |
| Annual Growth Rate | 8.06% |
| 5-Year Change | 33.75% |
| 10-Year Change | 91.43% |
| Growth Volatility | 3.07 |
Daewon Pharm - Net Assets Trend (2011–2024)
This chart illustrates how Daewon Pharm's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Daewon Pharm (2011–2024)
The table below shows the annual net assets of Daewon Pharm from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩284.58 Billion | +7.69% |
| 2023-12-31 | ₩264.26 Billion | +6.23% |
| 2022-12-31 | ₩248.77 Billion | +13.90% |
| 2021-12-31 | ₩218.40 Billion | +2.65% |
| 2020-12-31 | ₩212.77 Billion | +4.19% |
| 2019-12-31 | ₩204.22 Billion | +11.47% |
| 2018-12-31 | ₩183.20 Billion | +8.96% |
| 2017-12-31 | ₩168.13 Billion | +3.78% |
| 2016-12-31 | ₩162.01 Billion | +8.98% |
| 2015-12-31 | ₩148.66 Billion | +10.52% |
| 2014-12-31 | ₩134.51 Billion | +9.14% |
| 2013-12-31 | ₩123.25 Billion | +9.14% |
| 2012-12-31 | ₩112.92 Billion | +8.67% |
| 2011-12-31 | ₩103.92 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Daewon Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 26207671220000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩262.08 Billion | 95.20% |
| Other Components | ₩13.21 Billion | 4.80% |
| Total Equity | ₩275.28 Billion | 100.00% |
Daewon Pharm Competitors by Market Cap
The table below lists competitors of Daewon Pharm ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Unibel S.A
PA:UNBL
|
$93.99 Million |
|
Krishana Phoschem Limited
NSE:KRISHANA
|
$94.00 Million |
|
KALTURA INC. DL -0001
F:73Q
|
$94.00 Million |
|
Verkkokauppa.com Oyj
HE:VERK
|
$94.00 Million |
|
Fineotex Chemical Limited
NSE:FCL
|
$93.97 Million |
|
MYFAIR GOLD CORP.
F:9M5
|
$93.94 Million |
|
Shenzhen L&A Design Holding Limited
SHE:300949
|
$93.92 Million |
|
Barton Gold Holdings Ltd
AU:BGD
|
$93.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Daewon Pharm's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 266,198,938,600 to 275,284,566,430, a change of 9,085,627,830 (3.4%).
- Net income of 14,209,540,700 contributed positively to equity growth.
- Dividend payments of 6,358,815,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩14.21 Billion | +5.16% |
| Dividends Paid | ₩6.36 Billion | -2.31% |
| Other Changes | ₩1.23 Billion | +0.45% |
| Total Change | ₩- | 3.41% |
Book Value vs Market Value Analysis
This analysis compares Daewon Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.83x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.32x to 0.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩8019.68 | ₩10600.00 | x |
| 2018-12-31 | ₩8761.74 | ₩10600.00 | x |
| 2019-12-31 | ₩9785.93 | ₩10600.00 | x |
| 2020-12-31 | ₩10382.50 | ₩10600.00 | x |
| 2021-12-31 | ₩10335.27 | ₩10600.00 | x |
| 2022-12-31 | ₩11966.66 | ₩10600.00 | x |
| 2023-12-31 | ₩12558.89 | ₩10600.00 | x |
| 2024-12-31 | ₩12843.70 | ₩10600.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Daewon Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.16%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.38%
- • Asset Turnover: 1.03x
- • Equity Multiplier: 2.12x
- Recent ROE (5.16%) is below the historical average (9.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 9.10% | 6.79% | 0.99x | 1.35x | ₩-937.14 Million |
| 2012 | 8.55% | 6.96% | 0.94x | 1.31x | ₩-1.62 Billion |
| 2013 | 10.06% | 7.75% | 0.99x | 1.31x | ₩69.83 Million |
| 2014 | 11.75% | 8.64% | 1.01x | 1.35x | ₩2.34 Billion |
| 2015 | 11.94% | 8.19% | 1.11x | 1.31x | ₩2.88 Billion |
| 2016 | 12.54% | 8.41% | 1.12x | 1.33x | ₩4.10 Billion |
| 2017 | 6.39% | 4.05% | 1.17x | 1.35x | ₩-6.06 Billion |
| 2018 | 12.94% | 8.28% | 1.04x | 1.50x | ₩5.39 Billion |
| 2019 | 13.32% | 8.59% | 0.97x | 1.60x | ₩6.79 Billion |
| 2020 | 8.25% | 5.72% | 0.92x | 1.57x | ₩-3.75 Billion |
| 2021 | 3.19% | 1.97% | 0.82x | 1.96x | ₩-14.94 Billion |
| 2022 | 12.73% | 6.67% | 1.06x | 1.81x | ₩6.85 Billion |
| 2023 | 8.98% | 4.54% | 1.04x | 1.91x | ₩-2.70 Billion |
| 2024 | 5.16% | 2.38% | 1.03x | 2.12x | ₩-13.32 Billion |
Industry Comparison
This section compares Daewon Pharm's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Daewon Pharm (003220) | ₩263.87 Billion | 9.10% | 1.30x | $93.98 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |